CD8A and neoplasm: Giving the anti-CTLA-4 mAb treatment several days before the vaccine stimulation resulted in the depletion of Tregs and the expansion of antigen-specific CD8+ T cells in vitro and led to an enhanced anti-tumor effect in vivo (112).